Tilray Brands (TLRY) Non-Current Assets (2017 - 2026)
Tilray Brands' (TLRY) quarterly Non-Current Assets came in at $1.5 billion in Q2 2026, down 22.86% YoY from $2.0 billion in Q2 2025, and up 13.27% on a QoQ basis from $1.4 billion in Q1 2026.
Tilray Brands (TLRY) Non-Current Assets (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Non-Current Assets data on file, last reported at $1.5 billion in Q2 2026.
- Quarterly Non-Current Assets fell 22.86% year-over-year to $1.5 billion in Q2 2026, while the trailing twelve-month figure through May 2026 was $5.6 billion (down 36.91% YoY) and the FY2026 annual result came in at $1.5 billion, down 22.86% from the prior year.
- Non-Current Assets improved to $1.5 billion in Q2 2026, from $1.4 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $5.1 billion in Q1 2022 to a low of -$67.4 million in Q1 2025.
- A 5-year average of $3.1 billion and a median of $3.5 billion in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets sank 101.88% — and 2026, when it soared 2113.13%.
- Tracing TLRY's Non-Current Assets over 5 years: stood at $4.7 billion in 2022, then dropped by 20.84% to $3.7 billion in 2023, then fell by 5.53% to $3.5 billion in 2024, then slumped by 60.7% to $1.4 billion in 2025, then increased by 12.17% to $1.5 billion in 2026.
- The last three Non-Current Assets figures came in at $1.5 billion (Q2 2026), $1.4 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Tilray Brands | 519.72 Mn | 285.09 Mn | 90.52 Mn | 1.54 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 1.54 Bn |
| Feb 28, 2026 | 1.36 Bn |
| Nov 30, 2025 | 1.37 Bn |
| Aug 31, 2025 | 1.38 Bn |
| May 31, 2025 | 1.99 Bn |
| Feb 28, 2025 | -67.36 Mn |
| Nov 30, 2024 | 3.48 Bn |
| Aug 31, 2024 | 3.54 Bn |
| May 31, 2024 | 3.54 Bn |
| Feb 29, 2024 | 3.58 Bn |
| Nov 30, 2023 | 3.69 Bn |
| Aug 31, 2023 | 3.57 Bn |
| May 31, 2023 | 3.53 Bn |
| Feb 28, 2023 | 3.62 Bn |
| Nov 30, 2022 | 4.66 Bn |
| Aug 31, 2022 | 4.68 Bn |
| May 31, 2022 | 4.65 Bn |
| Feb 28, 2022 | 5.12 Bn |
| Nov 30, 2021 | 5.06 Bn |
| Aug 31, 2021 | 5.14 Bn |